天域生物科技股份有限公司 关于归还募集资金及继续使用部分闲置募集资金暂时 补充流动资金的公告 证券代码：603717 证券简称：天域生物 公告编号：2025-057 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 截至 2025 年 08 月 12 日，天域生物科技股份有限公司（以下简称"公司"， 曾用名"天域生态环境股份有限公司"）已将前次暂时补充流动资金的募集资金 7,400 万元归还至募集资金专户。 公司拟继续使用不超过人民币 6,150 万元的闲置募集资金暂时补充流动 资金，使用期限自董事会审议通过之日起不超过 12 个月。 公司于 2025 年 08 月 12 日分别召开第四届董事会第四十二次会议和第四届 监事会第三十五次会议，审议通过了《关于继续使用部分闲置募集资金暂时用于 补充流动资金的议案》，同意公司在确保不影响募集资金投资项目实施及募集资 金使用的情况下，继续使用不超过 6,150 万元的闲置募集资金暂时补充公司流动 资金，使用期限自董事会审议通过之日起不超过 12 个月。具体情况如下： 一、 ...

Group 1 - The core viewpoint of the announcement is to provide the main operational data for the pig farming business of Tianyu Biotechnology Co., Ltd. for July 2025, highlighting significant changes in sales volume and revenue compared to previous periods [1][3]. - In July 2025, the company sold 17,200 pigs, generating a revenue of 21.03 million yuan, with month-on-month changes of -45.86% in sales volume and -43.89% in revenue, while year-on-year changes were +3.81% in sales volume and -37.23% in revenue [1]. - For the period from January to July 2025, the cumulative sales volume reached 221,400 pigs, representing a year-on-year increase of 19.93%, and the cumulative revenue was 332.56 million yuan, reflecting an 11.35% year-on-year increase [1]. Group 2 - As of the end of July 2025, the company's pig inventory stood at 163,800 pigs, showing a year-on-year increase of 10.26% and a month-on-month increase of 13.43% [1]. - The announcement includes a note that the operational data is unaudited and may differ from the data disclosed in regular reports, serving only as a reference for investors [3]. - The company cautions that future sales volume and revenue may experience monthly fluctuations due to significant price volatility in the pig market and changes in the company's breeding schedule [3].

人民财讯8月7日电，天域生物（603717）8月7日晚公告，2025年7月，公司销售生猪1.72万头，销售收 入2103.14万元，环比变动分别为-45.86%、-43.89%，同比变动分别为3.81%、-37.23%。2025年1-7月， 公司累计销售生猪22.14万头，同比上升19.93%；累计销售收入3.33亿元，同比上升11.35%。 ...

证券代码：603717 证券简称：天域生物 公告编号：2025-056 | | 月份 | | 销售数量（万头） | | 销售收入（万元） | | 期末库存量 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 当月 | 累计 | 当月 | 累计 | （万头） | | 2025 | 年 1 | 月 | 3.94 | 3.94 | 6,115.20 | 6,115.20 | 17.01 | | 2025 | 年 2 | 月 | 3.12 | 7.06 | 4,270.88 | 10,386.08 | 15.14 | | 2025 | 年 3 | 月 | 4.16 | 11.25 | 7,047.03 | 17,433.11 | 14.00 | | 2025 | 年 4 | 月 | 3.51 | 14.76 | 5,932.95 | 23,366.06 | 13.32 | | 2025 | 年 5 | 月 | 2.48 | 17.24 | 4,038.75 | 27,404.81 | 14.14 | | 2025 | 年 6 | 月 | 3.18 ...

天域生物（603717）(603717.SH)发布公告，2025年7月，公司销售生猪1.72万头，销售收入2103.14万 元，环比变动分别为-45.86%、-43.89%，同比变动分别为3.81%、-37.23%。2025年1-7月，公司累计销 售生猪22.14万头，同比上升19.93%;累计销售收入3.33亿元，同比上升11.35%。2025年7月末，公司生猪 存栏16.38万头，同比上升10.26%，环比上升13.43%。 ...

Summary of Key Points Core Viewpoint - The announcement details the share pledge situation of the company's major shareholders, highlighting the percentage of shares pledged and the implications for the company's operations and governance. Group 1: Shareholding and Pledge Details - As of the announcement date, Mr. Luo Weiguo holds 37,251,829 shares, accounting for 12.84% of the total share capital, while Mr. Shi Dongwei holds 32,338,800 shares, representing 11.15% of the total share capital [1] - After the pledge, Mr. Luo has pledged a total of 22,000,000 shares, which is 59.06% of his holdings and 7.58% of the total share capital; Mr. Shi has pledged 29,000,000 shares, which is 89.68% of his holdings and 9.99% of the total share capital [1] - Together, Mr. Luo and Mr. Shi hold 69,590,629 shares, making up 23.98% of the total share capital, and after the pledge, they have pledged a total of 51,000,000 shares, which is 73.29% of their holdings and 17.58% of the total share capital [1] Group 2: Legal and Financial Status - Due to a legal dispute, 14,375,524 shares held by Mr. Luo are frozen, and 3,181,856 shares held by Mr. Shi are also frozen due to a contractual dispute [2] - Both Mr. Luo and Mr. Shi have good credit status and possess the financial capability to repay, with repayment funds sourced from their own resources, indicating that the pledge risk is controllable [2] - There is currently no risk of forced liquidation or margin call, and if a warning occurs, they will take measures such as additional pledges or early repayments [2] Group 3: Impact on the Company - The share pledge will not affect the company's main business, financing credit, financing costs, or ongoing operational capabilities [2] - The pledge will not influence the shareholders' ability to appoint directors to the company, nor will it affect the relationship between shareholders and the company regarding property, business, assets, or personnel [2] - The stability of control, shareholding structure, and daily management of the company will remain unaffected by this pledge [2]

Core Points - The announcement details the pledge of shares by the controlling shareholders of Tianyu Biotechnology Co., Ltd, specifically Mr. Luo Weiguo and Mr. Shi Dongwei [1][2] Group 1: Shareholding and Pledge Details - As of the announcement date, Mr. Luo Weiguo holds 37,251,829 shares, accounting for 12.84% of the total share capital, while Mr. Shi Dongwei holds 32,338,800 shares, accounting for 11.15% [1] - After the pledge, Mr. Luo has pledged a total of 22,000,000 shares, which is 59.06% of his holdings and 7.58% of the total share capital; Mr. Shi has pledged 29,000,000 shares, which is 89.68% of his holdings and 9.99% of the total share capital [1] - Together, Mr. Luo and Mr. Shi hold 69,590,629 shares, representing 23.98% of the total share capital, and after the pledge, they have pledged a total of 51,000,000 shares, which is 73.29% of their holdings and 17.58% of the total share capital [1] Group 2: Legal and Financial Status - Due to a legal dispute, 14,375,524 shares held by Mr. Luo are judicially frozen, and 3,181,856 shares held by Mr. Shi are also frozen due to a contractual dispute [2] - Both shareholders have good credit status and possess the financial capability to repay, with repayment funds sourced from their own funds; the risk associated with the pledged shares is controllable, and there is currently no risk of forced liquidation [2][3] Group 3: Impact on the Company - The pledged shares will not affect the company's main business, financing credit, financing costs, or ongoing operational capabilities [3] - The pledge will not influence the shareholders' ability to appoint directors to the company, nor will it affect the relationship between shareholders and the company regarding property, business, assets, or personnel [3]

天域生物科技股份有限公司（以下简称"公司"）于 2025 年 08 月 05 日收到 公司控股股东、实际控制人罗卫国先生及史东伟先生的书面函告，获悉其所持有 的公司部分股份办理了质押登记手续，具体情况如下： 证券代码：603717 证券简称：天域生物 公告编号：2025-055 天域生物科技股份有限公司 关于控股股东所持公司部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、上市公司股份质押 1、本次股份质押的基本情况 | | 是否 | 本次质押 | 是否 | | | | 占其所 | 占公 | 质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | 为控 | | | 质押起始 | 质押到期 | | | 司总 | 融资 | | 名称 | 股股 | 股数 | 补充 | 日 | 日 | 质权人 | 持股份 | 股本 | 资金 | | | | （股） | 质押 | | | | 比例 | | | | | 东 | ...

天眼查商业履历信息显示，天域生物科技股份有限公司，成立于2000年，位于重庆市，是一家以从事公 共设施管理业为主的企业。企业注册资本29014.624万人民币，实缴资本11964万人民币。公司法定代表 人为史东伟。 资金流向方面，今日主力资金净流出1157.09万元，占比成交额18.55%。其中，超大单净流出512.20万 元、占成交额8.21%，大单净流出644.90万元、占成交额10.34%，中单净流出流入399.11万元、占成交 额6.4%，小单净流入757.98万元、占成交额12.15%。 天域生物最新一期业绩显示，截至2025一季报，公司营业总收入2.25亿元、同比增长6.68%，归属净利 润1376.82万元，同比增长52.50%，扣非净利润638.92万元，同比减少457.16%，流动比率1.127、速动比 率0.955、资产负债率75.91%。 金融界消息 截至2025年7月31日收盘，天域生物（603717）报收于7.46元，下跌1.97%，换手率2.85%， 成交量8.28万手，成交金额6237.73万元。 通过天眼查大数据分析，天域生物科技股份有限公司共对外投资了62家企业，参与招投标项 ...

7月29日晚间，天域生物（SH603717，股价7.61元，市值22.08亿元）披露，近期，公司向青海省海西蒙 古族藏族自治州中级人民法院申请依法强制执行刘炳生向公司支付一次性现金补偿款4329.53万元及已 预缴仲裁费31.43万元。 2022年3月，天域生物与青海聚之源新材料有限公司（以下简称聚之源）、刘炳生签订《股权战略投资 协议》，以货币资金2.1亿元增资聚之源并获得35%的股权。 但由于对方未完成业绩承诺且未能提供有效的财务凭证，天域生物向上海仲裁委员会提起仲裁。不过， 仲裁结束后，对方仍未支付业绩补偿款，因此天域生物向法院申请强制执行。 并购资产连亏三年 2022年2月，天域生物披露了一份对外投资公告，拟以现金不超过6.1亿元增资聚之源，增资完成后持有 聚之源51%的股权，并获得其控制权。不过，2022年3月，天域生物更改了上述投资计划，新交易方案 为公司通过增资的形式向聚之源投资2.1亿元，以获得其35%股权。 业绩对赌内容显示，此次交易的业绩承诺方为聚之源及其实控人刘炳生，业绩承诺补偿义务人为刘炳 生。聚之源2022年至2024年承诺经审计的累计扣非净利润为9亿元。 根据《股权投资协议》约定的 ...